Clinical trial

A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

NCT00216632

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-03-01

PhasePHASE4

Study timeline

Study start (unknown)2005-03-01Date precision: month

Registry last updated2012-12-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Psychotic Disordersunresolved

Interventions

risperidoneDRUG · verified · RxNorm: risperidone

Sponsors & collaborators

Janssen Pharmaceutica N.V., Belgiumlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00216632 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.